Hit enter to search or ESC to close
Hepion PharmaceuticalsHepion Pharmaceuticals
  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
Hepion Pharmaceuticals

Hepion Tackles NASH in P2 with Cyclophilin Inhibitor [Breaking Biotech]

By HepionOctober 11, 2020December 2nd, 2020Media Placements, Videos
No Comments
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
January 05, 2021

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Share Tweet Share Pin
Get Important News and Updates by Email Subscribe

© 2020 Hepion Pharmaceuticals | Disclaimer & Terms of Use | WDDI

  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers